obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
One of the greatest threats to the long-term well being of human remains in museum collections is improper storage and packing. Proper storage of human remains is not only necessary for their physical preservation, but it also demonstrates the respect that sensitive materials such as these should be accorded. The ideal storage location for sacred artifacts and human remains is a designated space away from the rest of the collection; however, there are often many constraints which prevent this from being possible. At the minimum, ethical guidelines suggest that remains from different individuals should be stored in separate boxes or compartments from each other. Generally speaking, human remains are best preserved in cool, dark, dry conditions while wrapped in acid-free (non-buffered) tissue and packing materials. Corporeal materials should not be stored in or near any wood or in any containers which previously housed wood due to potentially increased lignin levels, which produce an acid that can lead to the deterioration of DNA and proteins in the remains. Excessive exposure to light should be avoided in order to prevent bleaching of materials, especially bone.
This regulates the reaction catalyzing fructose 2,6-bisphosphate (a potent activator of phosphofructokinase-1, the enzyme that is the primary regulatory step of glycolysis) by slowing the rate of its formation, thereby inhibiting the flux of the glycolysis pathway and allowing gluconeogenesis to predominate. This process is reversible in the absence of glucagon (and thus, the presence of insulin). Glucagon stimulation of PKA inactivates the glycolytic enzyme pyruvate kinase, inactivates glycogen synthase, and activates hormone-sensitive lipase, which catabolizes glycerides into glycerol and free fatty acid(s), in hepatocytes. Glucagon also inactivates acetyl-CoA carboxylase (ACC), which creates malonyl-CoA from acetyl-CoA, through cAMP-dependent and/or cAMP-independent kinases. Malonyl-CoA is a product formed by ACC during denovo synthesis and an allosteric inhibitor of carnitine palmitoyltransferase I (CPT1), a mitochondrial enzyme important for bringing fatty acids into the intermembrane space of the mitochondria for β-oxidation. Glucagon decreases malonyl-CoA through inhibition of acetyl-CoA carboxylase and through reduced glycolysis through its aforementioned reduction in Fructose 2,6-bisphosphate. Thus, reduction in malonyl-CoA is a common regulator for the increased fatty acid metabolism effects of glucagon.
This infuriated American colonists and led to the Boston Tea Party, where 90,000 pounds of EIC tea were dumped into the Boston Harbor. As news spread, tea was destroyed throughout the colonies. In Greenwich New Jersey for example, chests of tea were burned in Market Square. As a consequence of these acts and the American revolution (1765–1791), tea drinking became seen as unpatriotic. One article in the Boston Gazette on 15 August, 1768 stated: “Let us abjure the poisonous baneful plant and its odious infusion – poisonous and odious, I mean, not on account of its physical qualities but on account of the political diseases and death that are connected with every particle of it.” Boycotts of tea by revolutionary patriots led to an increase in consumption of other beverages, such as coffee, yaupon tea, or herbal teas infused with peppermint, sage or dandelions. In spite of the distaste for tea that was fueled by the revolution, tea continued to be used by Americans, especially after the war. For example, George Washington regularly had tea for breakfast and dinner, in the English fashion. American merchants Samuel Shaw and Robert Morris sent the first merchant ship to China (the Empress of China) and soon Chinese tea was being shipped to America by American merchant vessels.
Sources: en.wikipedia.org
==== Electrochemical fluorination ==== Electrochemical fluorination (ECF) (also known as the Simons' process) involves electrolysis of a substrate dissolved in hydrogen fluoride. As fluorine is itself manufactured by the electrolysis of hydrogen fluoride, ECF is a rather more direct route to fluorocarbons. The process proceeds at low voltage (5 – 6 V) so that free fluorine is not liberated. The choice of substrate is restricted as ideally it should be soluble in hydrogen fluoride. Ethers and tertiary amines are typically employed. To make perfluorohexane, trihexylamine is used, for example:
Ds,eff = aDs + b/ (1022Ds) = 8.051e−6Ds+0.999/(1022Ds), Eq. 3 where Ds = (1/(dC/dx))10−11 assuming a constant flux and taken as unity. The eq. (2) and assumption of unity is a matter of further investigation. Several commercial companies and university laboratories provide obsidian hydration services.
The Booth Brewing Co. is a microbrewery headquartered in Seoul, South Korea. The brewery was founded in 2015 by Sunghoo Yang, a former investment analyst, Heeyoon Kim, a former Korean medical doctor, and Daniel Tudor, a journalist for The Economist. They had been operating a pizza pub since 2013. In 2015, they acquired a brewing facility in Eureka, California, previously owned by Lost Coast Brewery. They are well known for Taedonggang Pale Ale, a collaboration with Danish microbrewery Mikkeller, and also for being the second non-U.S. craft brewer to produce beer in their own facility in the United States.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.